14 completed, 5 recruiting, 1 active not recruiting, 1 not yet recruiting. 8 Phase 3, 5 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 7, Not yet recruiting 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Bempedoic acid: new trials by email Literature Review of Bempedoic acid trials Research Report on Bempedoic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome bempedoic acid, Ezetimibe, High-Intensity Statin Therapy - Acute Coronary Syndromes, Dyslipidemia | Phase 4 | Recruiting | Taipei Medical University Hospital | 400 | 2026-08-26 | 2026-09-17 |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin Bempedoic acid, Ezetimibe, Atorvastatin - Healthy Subjects | Phase 1 | Completed | Daiichi Sankyo | 58 | 2025-12-09 | 2026-02-27 |
| Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy Bempedoic acid - Hypercholesterolemia | Recruiting | Federico II University | 1500 | 2025-11-04 | 2026-01-29 | |
| A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin Bempedoic acid, Ezetimibe, Atorvastatin - Healthy Subjects | Phase 1 | Completed | Daiichi Sankyo | 58 | 2025-10-28 | 2026-02-02 |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin Bempedoic acid, Ezetimibe, Rosuvastatin - Healthy Subjects | Phase 1 | Completed | Daiichi Sankyo | 58 | 2025-10-07 | 2025-12-18 |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin Bempedoic acid, Ezetimibe, Rosuvastatin - Healthy Subjects | Phase 1 | Completed | Daiichi Sankyo | 58 | 2025-09-29 | 2025-12-16 |
| A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Bempedoic acid, Ezetimibe, Rosuvastatin - Primary Hypercholesterolemiia, Mixed Dyslipidemia | Active not recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2000 | 2025-02-12 | 2026-09-30 | |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. AZD0780, Ezetimibe, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 81 | 2024-12-20 | 2025-11-10 |
| A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 301 | 2024-07-08 | 2026-03-27 |
| Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Bempedoic acid - Type 2 Diabetes, Non Alcholic Fatty Liver Disease | Not applicable | Recruiting | Medanta, The Medicity, India | 100 | 2023-10-15 | 2025-06-13 |
| Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) Bempedoic acid, Placebo - Dyslipidemias, Cardiovascular Diseases | Phase 2 | Recruiting | Priscilla Hsue, MD | 121 | 2023-03-01 | 2025-12-17 |
| A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Bempedoic acid - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 31 | 2023-01-12 | 2026-07-17 |
| Bempedoic Acid Pregnancy Surveillance Program Bempedoic Acid, Bempedoic Acid / Ezetimibe - Pregnancy, Hyperlipidemias | Recruiting | Esperion Therapeutics, Inc. | 20 | 2021-09-01 | 2024-05-17 | |
| A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe - Hyperlipidemias | Phase 3 | Completed | Esperion Therapeutics, Inc. | 382 | 2017-10-23 | 2020-04-08 |
| Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) bempedoic acid - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 3 | Completed | Esperion Therapeutics, Inc. | 1462 | 2017-02-03 | 2021-03-01 |
| Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) Bempedoic acid, Ezetimibe, Placebo - Hypercholesterolemia, Atherosclerosis | Phase 3 | Completed | Esperion Therapeutics, Inc. | 269 | 2016-11-29 | 2020-05-11 |
| Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk bempedoic acid, placebo - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 3 | Completed | Esperion Therapeutics, Inc. | 779 | 2016-11-18 | 2020-04-27 |
| Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant bempedoic acid, placebo - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 3 | Completed | Esperion Therapeutics, Inc. | 345 | 2016-11-16 | 2020-04-03 |
| Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) ETC-1002, Placebo - Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases | Phase 3 | Completed | Esperion Therapeutics, Inc. | 2230 | 2016-01-21 | 2020-05-11 |
Showing 20 of 21. Sign in to see all of them.
Hypercholesterolemia (12) · Atherosclerosis (7) · Hyperlipidemias (7) · Dyslipidemias (3) · Hyperlipoproteinemia Type II (2) · Acute Coronary Syndrome (1) · Angina, Unstable (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Type 2 (1) · HIV Infections (1) · Non-ST Elevated Myocardial Infarction (1) · ST Elevation Myocardial Infarction (1)
Esperion Therapeutics, Inc. (9) · Daiichi Sankyo (5) · AstraZeneca (1) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1) · Federico II University (1) · Medanta, The Medicity, India (1) · Merck Sharp & Dohme LLC (1) · Priscilla Hsue, MD (1) · Taipei Medical University Hospital (1)
United States (12) · Canada (4) · Germany (4) · Portugal (4) · Spain (4) · Italy (3) · United Kingdom (3) · Netherlands (2) · Taiwan (2) · Argentina (1) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · India (1)
Ron Haberman, MD (5) · Christine Broestl, MS (1) · Chun-Yao Huang, MD, PhD (1) · Mary McGowan, MD (1) · Priscilla Hsue, MD (1)
PMID 32609313, PMID 35916348, PMID 19938117, PMID 22025886, PMID 22431131, PMID 22554256, PMID 25482832, PMID 29910030, PMID 30865796, PMID 30922146, PMID 31357887, PMID 34887111, PMID 34909677, PMID 36813656, PMID 38085172, PMID 42017875
2016 (2), 2015 (1), 2023 (1), 2025 (1)